Vol 8, No 1 (2022)
Review paper
Published online: 2022-06-17

open access

Page views 4760
Article views/downloads 279
Get Citation

Connect on Social Media

Connect on Social Media

Fibromyalgia — new horizons

Edyta Prokop-Przybył1, Przemysław Keczmer2, Włodzimierz Samborski2
Rheumatology Forum 2022;8(1):27-30.

Abstract

Fibromyalgia (FM) is a chronic non-inflammatory disease characterised by generalised pain and soft tissue tenderness, muscle stiffness, insomnia, fatigue, depression and cognitive impairment. There are still many hypotheses for the aetiopathology of FM and pathophysiological mechanisms of FM are not yet well-understood. This article presents the current reports on the difficult diagnosis options and challenges in the treatment of this disease.

Article available in PDF format

View PDF Download PDF file

References

  1. https://www.cdc.gov/arthritis/basics/fibromyalgia.htm (23 May 2022).
  2. Marques AP, Santo Ad, Berssaneti AA, et al. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed. 2017; 57(4): 356–363.
  3. Cabo-Meseguer A, Cerdá-Olmedo G, Trillo-Mata JL. Fibromyalgia: Prevalence, epidemiologic profiles and economic costs. Med Clin (Barc). 2017; 149(10): 441–448.
  4. Häuser W, Brähler E, Ablin J, et al. Modified 2016 American College of Rheumatology Fibromyalgia Criteria, the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks-American Pain Society Pain Taxonomy, and the Prevalence of Fibromyalgia. Arthritis Care Res (Hoboken). 2021; 73(5): 617–625.
  5. Atzeni F, Talotta R, Masala IF, et al. One year in review 2019: fibromyalgia. Clin Exp Rheumatol. 2019; 37 Suppl 116(1): 3–10.
  6. Vijayan S, Klerman EB, Adler GK, et al. Thalamic mechanisms underlying alpha-delta sleep with implications for fibromyalgia. J Neurophysiol. 2015; 114(3): 1923–1930.
  7. Bennett RM, Cook DM, Clark SR, et al. Hypothalamic-pituitary-insuline-like growth factor-laxis dysfunction in patients with fi bromyalgia. J Rheumatol. 1997; 24: 1384–1389.
  8. Samborski W. Fibromialgia — aktualne zasady rozpoznawania choroby, nowe propozycje dotyczące patogenezy i leczenia. Forum Reumatol. 2015; 1(1): 5–11.
  9. D'Agnelli S, Arendt-Nielsen L, Gerra MC, et al. Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers. Mol Pain. 2019; 15: 1744806918819944.
  10. Grayston R, Czanner G, Elhadd K, et al. A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. Semin Arthritis Rheum. 2019; 48(5): 933–940.
  11. Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016; 157(7): 1382–1386.
  12. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017; 76(2): 318–328.
  13. Goebel A, Krock E, Gentry C, et al. Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest. 2021; 131(13).